Patients with advanced pancreatic and biliary cancer appear vulnerable to SARS-CoV-2 Omicron variant: An observational study during the COVID-19 outbreak in Shanghai
BackgroundThe COVID-19 pandemic has spread rapidly across the globe. Cancer patients have a higher risk of severe infections and associated mortality than the general population. However, the lethal effect of Omicron-variant affection on advanced pancreatic and biliary cancer patients is still not c...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-03-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1115293/full |
| _version_ | 1797865964014927872 |
|---|---|
| author | Tao Han Lujun Chen Jia Gu Shen Wu Maiweilan Maihemuti Jue Yang Hao Wang Jun Wu Yue Zhang Yun Cong Jiening Wang Tingsong Chen |
| author_facet | Tao Han Lujun Chen Jia Gu Shen Wu Maiweilan Maihemuti Jue Yang Hao Wang Jun Wu Yue Zhang Yun Cong Jiening Wang Tingsong Chen |
| author_sort | Tao Han |
| collection | DOAJ |
| description | BackgroundThe COVID-19 pandemic has spread rapidly across the globe. Cancer patients have a higher risk of severe infections and associated mortality than the general population. However, the lethal effect of Omicron-variant affection on advanced pancreatic and biliary cancer patients is still not clear. Herein, we designed an observational study to shed light on the influence of the Omicron variant on this so-called “King of Cancer” and improve management of these patients with COVID-19 in the future.MethodsOmicron-infected patients with advanced pancreatic and biliary cancer were enrolled from 15 April to 31 May 2022. Four groups were set up in this study: Group 1, Omicron-infected cancer patients (N = 4); Group 2, non-infected cancer patients (N = 4); Group 3, infected non-cancer-afflicted subjects (N = 4); Group 4, non-infected non-cancer-afflicted subjects (N = 4). On Days 0, 7, and 14 after infection, the blood samples were collected dynamically from all subjects. The primary endpoints were disease severity and survival.ResultsAt the endpoint of this observational study, Patient Nos. 2, 3, and 4 died separately on Days 11, 25, and 13 after viral infection. All of them had advanced cancer, with a death rate of up to 75%. Group 1 presented an overall T-cell exhaustion status compared with other groups. Group 1 had obviously lower T-cell populations and higher B-cell percentages and CD4+T/CD8+T ratios (P <0.05). Time-course cytokine monitoring results showed that IL-1β was significantly decreased in Group 1 (P <0.05) and generally kept at a low level without obvious fluctuation. IL-6 was markedly increased in infected cancer patients (P <0.01) but remained at a low level and had no apparent change during the whole infection process in non-cancer-afflicted subjects. Furthermore, several inflammatory parameter indexes indicated a tight association of Omicron infection with the disease course and prognosis of Omicron-infected cancer patients.ConclusionsAdvanced pancreatic and biliary cancer patients with Omicron infection have severe symptoms and poor outcomes. More attention, protective measures, and routine healthcare services should be recommended to these vulnerable populations in clinical practice during the pandemic in the foreseeable future. |
| first_indexed | 2024-04-09T23:16:37Z |
| format | Article |
| id | doaj.art-9da87e512be84c35bcf106c206390951 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-09T23:16:37Z |
| publishDate | 2023-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-9da87e512be84c35bcf106c2063909512023-03-22T06:14:30ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-03-011310.3389/fonc.2023.11152931115293Patients with advanced pancreatic and biliary cancer appear vulnerable to SARS-CoV-2 Omicron variant: An observational study during the COVID-19 outbreak in ShanghaiTao Han0Lujun Chen1Jia Gu2Shen Wu3Maiweilan Maihemuti4Jue Yang5Hao Wang6Jun Wu7Yue Zhang8Yun Cong9Jiening Wang10Tingsong Chen11Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, ChinaThe General Hospital of Northern Theater Command Training Base for Graduate, China Medical University, Shenyang, ChinaDepartment of Otolaryngology, The First Affiliated Hospital of China Medical University, Shenyang, ChinaDepartment of Oncology, Seventh People’s Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai, ChinaDepartment of Medical Oncology, The First Hospital of China Medical University, Shenyang, ChinaDepartment of Oncology, Seventh People’s Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai, ChinaDepartment of Oncology, Seventh People’s Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai, ChinaThe General Hospital of Northern Theater Command Training Base for Graduate, China Medical University, Shenyang, ChinaDepartment of Oncology, Seventh People’s Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai, ChinaDepartment of Oncology, Seventh People’s Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai, ChinaDepartment of Oncology, Seventh People’s Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai, ChinaDepartment of Oncology, Seventh People’s Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai, ChinaBackgroundThe COVID-19 pandemic has spread rapidly across the globe. Cancer patients have a higher risk of severe infections and associated mortality than the general population. However, the lethal effect of Omicron-variant affection on advanced pancreatic and biliary cancer patients is still not clear. Herein, we designed an observational study to shed light on the influence of the Omicron variant on this so-called “King of Cancer” and improve management of these patients with COVID-19 in the future.MethodsOmicron-infected patients with advanced pancreatic and biliary cancer were enrolled from 15 April to 31 May 2022. Four groups were set up in this study: Group 1, Omicron-infected cancer patients (N = 4); Group 2, non-infected cancer patients (N = 4); Group 3, infected non-cancer-afflicted subjects (N = 4); Group 4, non-infected non-cancer-afflicted subjects (N = 4). On Days 0, 7, and 14 after infection, the blood samples were collected dynamically from all subjects. The primary endpoints were disease severity and survival.ResultsAt the endpoint of this observational study, Patient Nos. 2, 3, and 4 died separately on Days 11, 25, and 13 after viral infection. All of them had advanced cancer, with a death rate of up to 75%. Group 1 presented an overall T-cell exhaustion status compared with other groups. Group 1 had obviously lower T-cell populations and higher B-cell percentages and CD4+T/CD8+T ratios (P <0.05). Time-course cytokine monitoring results showed that IL-1β was significantly decreased in Group 1 (P <0.05) and generally kept at a low level without obvious fluctuation. IL-6 was markedly increased in infected cancer patients (P <0.01) but remained at a low level and had no apparent change during the whole infection process in non-cancer-afflicted subjects. Furthermore, several inflammatory parameter indexes indicated a tight association of Omicron infection with the disease course and prognosis of Omicron-infected cancer patients.ConclusionsAdvanced pancreatic and biliary cancer patients with Omicron infection have severe symptoms and poor outcomes. More attention, protective measures, and routine healthcare services should be recommended to these vulnerable populations in clinical practice during the pandemic in the foreseeable future.https://www.frontiersin.org/articles/10.3389/fonc.2023.1115293/fullpancreatic and biliary cancerCOVID-19SARS-CoV-2 omicronimmunosuppressionvulnerable population |
| spellingShingle | Tao Han Lujun Chen Jia Gu Shen Wu Maiweilan Maihemuti Jue Yang Hao Wang Jun Wu Yue Zhang Yun Cong Jiening Wang Tingsong Chen Patients with advanced pancreatic and biliary cancer appear vulnerable to SARS-CoV-2 Omicron variant: An observational study during the COVID-19 outbreak in Shanghai Frontiers in Oncology pancreatic and biliary cancer COVID-19 SARS-CoV-2 omicron immunosuppression vulnerable population |
| title | Patients with advanced pancreatic and biliary cancer appear vulnerable to SARS-CoV-2 Omicron variant: An observational study during the COVID-19 outbreak in Shanghai |
| title_full | Patients with advanced pancreatic and biliary cancer appear vulnerable to SARS-CoV-2 Omicron variant: An observational study during the COVID-19 outbreak in Shanghai |
| title_fullStr | Patients with advanced pancreatic and biliary cancer appear vulnerable to SARS-CoV-2 Omicron variant: An observational study during the COVID-19 outbreak in Shanghai |
| title_full_unstemmed | Patients with advanced pancreatic and biliary cancer appear vulnerable to SARS-CoV-2 Omicron variant: An observational study during the COVID-19 outbreak in Shanghai |
| title_short | Patients with advanced pancreatic and biliary cancer appear vulnerable to SARS-CoV-2 Omicron variant: An observational study during the COVID-19 outbreak in Shanghai |
| title_sort | patients with advanced pancreatic and biliary cancer appear vulnerable to sars cov 2 omicron variant an observational study during the covid 19 outbreak in shanghai |
| topic | pancreatic and biliary cancer COVID-19 SARS-CoV-2 omicron immunosuppression vulnerable population |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1115293/full |
| work_keys_str_mv | AT taohan patientswithadvancedpancreaticandbiliarycancerappearvulnerabletosarscov2omicronvariantanobservationalstudyduringthecovid19outbreakinshanghai AT lujunchen patientswithadvancedpancreaticandbiliarycancerappearvulnerabletosarscov2omicronvariantanobservationalstudyduringthecovid19outbreakinshanghai AT jiagu patientswithadvancedpancreaticandbiliarycancerappearvulnerabletosarscov2omicronvariantanobservationalstudyduringthecovid19outbreakinshanghai AT shenwu patientswithadvancedpancreaticandbiliarycancerappearvulnerabletosarscov2omicronvariantanobservationalstudyduringthecovid19outbreakinshanghai AT maiweilanmaihemuti patientswithadvancedpancreaticandbiliarycancerappearvulnerabletosarscov2omicronvariantanobservationalstudyduringthecovid19outbreakinshanghai AT jueyang patientswithadvancedpancreaticandbiliarycancerappearvulnerabletosarscov2omicronvariantanobservationalstudyduringthecovid19outbreakinshanghai AT haowang patientswithadvancedpancreaticandbiliarycancerappearvulnerabletosarscov2omicronvariantanobservationalstudyduringthecovid19outbreakinshanghai AT junwu patientswithadvancedpancreaticandbiliarycancerappearvulnerabletosarscov2omicronvariantanobservationalstudyduringthecovid19outbreakinshanghai AT yuezhang patientswithadvancedpancreaticandbiliarycancerappearvulnerabletosarscov2omicronvariantanobservationalstudyduringthecovid19outbreakinshanghai AT yuncong patientswithadvancedpancreaticandbiliarycancerappearvulnerabletosarscov2omicronvariantanobservationalstudyduringthecovid19outbreakinshanghai AT jieningwang patientswithadvancedpancreaticandbiliarycancerappearvulnerabletosarscov2omicronvariantanobservationalstudyduringthecovid19outbreakinshanghai AT tingsongchen patientswithadvancedpancreaticandbiliarycancerappearvulnerabletosarscov2omicronvariantanobservationalstudyduringthecovid19outbreakinshanghai |